Skip to main content

FLUCELVAX (Seqirus Pty Ltd)

Product name
Date registered
Evaluation commenced
Decision date
Approval time
218 (255 working days)
Active ingredients
Influenza virus haemagglutinin
Registration type

For the prevention of influenza caused by Influenza Virus, Types A and B contained in the vaccine. The vaccine is indicated for use in adults and children 6 months of age and older. For full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.

Help us improve the Therapeutic Goods Administration site